Individual patient data from neoadjuvant randomized breast cancer clinical trials with available data on pathologic complete ...

The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market ...

The pharma major beat analysts’ expectations in the fourth quarter of 2024, despite looming competition for its top heart ...

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

The American CEO of Swiss drugmaker Novartis on Friday warned that the United States' exit from the World Health Organization ...

Unlike other brands that release their ads days or weeks ahead of the Big Game, Novartis is waiting to unveil its commercial ...

Novartis AG's ( VTX:NOVN ) dividend will be increasing from last year's payment of the same period to $3.50 on 13th ...

Legos holds a PhD in physiology from Temple University and an MBA in finance from Villanova University. He has also written ...

Novartis AG (NYSE:NVS), a global healthcare powerhouse with a market capitalization of $208.27 billion, has recently transformed into a pure-play pharmaceutical company, sharpening its focus on its ...

Last year marked the first time in Pfizer’s 175-year history that the drugmaker shelled out the requisite millions for ...

Novartis AG's ( VTX:NOVN ) dividend will be increasing from last year's payment of the same period to $3.50 on 13th ...

The integration of AI in healthcare as a means by which to enhance diagnostic accuracy and treatment planning also appeared ...